NANIPRUS
-
| StockNo |
Product description |
| EB0280-424-14 |
NANIPRUS
AMPOULE 10 ML W/ 2 ML SOLVENT (SET OF 5) |
-
- COMPOSITION:
Nitroprusside sodium 30 mg - lyophilic injection form
ACTION:
A peripheral vasodilator with a strong myotropic action on smooth
muscle vascular cells, resulting in a marked vasodilating effect and
subsequent decrease of the arterial pressure. Its action is
short-lived due to its rapid degradation in the blood flow to
cyanogen and cyanide, which metabolize in the hepatocytes to form
thiocyanate (with slowly occurring moderate hypotensive effect). It
activates guanylate cyclase and increases the intracellular
concentration of cGMP, relaxes the tonic vascular muscles, improves
the pump function of the heart (by decreasing the pre- and
post-load), decreases thrombocyte aggregation.
INDICATIONS:
Hypertensive crises (except in pheochromocytoma), severe
hypertension which is resistant to treatment, hypertensive forms of
myocardial infarction (with acute venticular insufficiency); for
controlled angiopathy, peripheral arterial embolism.
CONTRAINDICATIONS:
Coaractation of the aorta, arteriovenous shunt, metabolic acidosis,
hypothyreoidism, hypovolemia, hypotension.
SIDE EFFECTS:
Reflex tachycardia, feeling of weakness and fatigue. Possible side
effects: headache, dizziness, perspiration, muscular spasms,
gastrointestinal disturbances, hearing and vision impairment (at
high doses). After prolonged (over 72 hours) application of higher
doses there is danger of thiocyanate intoxication with
methemoglobulinemia and irreversible hypotension (dizziness,
vomitting, diarrhea, confusion, hallucinations, muscular, cramps,
headache). |
DRUG INTERACTIONS:
General anesthetics and sedative drugs, ganglioblockers and
antihypertensive preparations increase the effect of Naniprus. The
effect of dihydroergotoxin methylase increases as well.
DOSAGE AND ADMINISTRATION:
The preparation is injected as a dropwise infusion protected from
light in the form of freshly prepared solution at injection rate of
0.5 ng/min/kg body weight (a patient with a weight of 70 kg receives
0.3 ml/min/kg), after dissolving the content of the vial (0.03) in 5
ml of 5 % glucose solution or in distilled water, the solution
obtained is poured into a bank with 5-10 % manitol solution or 5 %
glucose solution. The infusion rate may be regulated according to
arterial pressure values.
MEDICINAL FORM AND PACKAGE:
Lyophilic injection form in ampoules of 10 ml in packs of 5,
together with 5 ampoules of 5 ml with solvent.
STORAGE:
At temperature not lower than 0° C, in a place protected from
direct sunlight.
EXPIRY:
3 (three) years.
|
